{"url_path":"/sec/tara/8-k/2026-06-15/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-068774-index.html","accession_number":"0001213900-26-068774","cik":"0001359931","ticker":"TARA","issuer_name":"Protara Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-068774-index.html","primary_entity_key":"0001359931","primary_entity_name":"Protara Therapeutics, Inc."},"word_count":594,"has_tables":true,"body_markdown":"**Item 5.07 Submission of Matters to a Vote of Security\nHolders.**\n\n \n\nThe Annual Meeting of Stockholders (the “Annual\nMeeting”) of Protara Therapeutics, Inc. (the “Company”) was held on June 12, 2026. As of April 15, 2026, the record\ndate for the Annual Meeting, there were 55,060,500 shares of the Company’s common stock outstanding and entitled to vote. \nA summary of the matters voted upon at the Annual Meeting and the final voting results are set forth below.\n\n \n\n**Proposal 1. Election of Directors.**\n\n \n\nThe Company’s stockholders elected the\nthree persons listed below as Class III directors, each to serve on the Company’s Board of Directors until the Company’s 2029\nAnnual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:\n\n \n\n \n \n**Votes For**\n \n \n**Votes\nWithheld**\n \n \n**Broker\nNon-Votes**\n \n\nJesse Shefferman\n \n \n26,672,259\n \n \n \n4,241,606\n \n \n \n14,185,811\n \n\nBarry Flannelly, Pharm.D.\n \n \n25,409,066\n \n \n \n5,504,799\n \n \n \n14,185,811\n \n\nCynthia Smith\n \n \n22,371,125\n \n \n \n8,542,740\n \n \n \n14,185,811\n \n\n  \n\n**Proposal 2. Ratification of the Selection\nof Independent Registered Public Accounting Firm.**\n\n \n\nThe Company’s stockholders ratified the\nselection by the Company’s Audit Committee of the Board of Ernst and Young LLP as the Company’s independent registered public\naccounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:\n\n \n\n**Votes For**\n \n**Votes Against**\n \n**Abstentions**\n\n45,012,036\n \n74,615\n \n13,025\n\n \n\n**Proposal 3. Approval, on an Advisory Basis,\nof the Compensation of the Company’s Named Executive Officers.**\n\n \n\nThe Company’s stockholders approved, on\nan advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy\nstatement for the Annual Meeting. The final voting results are as follows:\n\n \n\n**Votes For**\n \n**Votes Against**\n \n**Abstentions**\n \n**Broker Non-Votes**\n\n29,208,205\n \n1,656,994\n \n48,666\n \n14,185,811\n\n \n\n**Proposal 4. Vote, on an Advisory Basis,\non the Frequency of the Say-On-Pay vote.**\n\n** **\n\nThe Company’s stockholders voted, on an\nadvisory basis, that the stockholder advisory vote to approve the compensation of the Company’s named executive officers should\noccur every one year. The final voting results are as follows:\n\n** **\n\n**One Year**\n \n**Two Years**\n \n**Three Years**\n \n**Abstentions**\n \n**Broker Non-Votes**\n\n26,766,824\n \n660,775\n \n3,441,894\n \n44,372\n \n14,185,811\n\n** **\n\n****\n\n1\n\n** **\n\n**Proposal 5. Approval of an Amendment to\nthe Protara Therapeutics, Inc. 2024 Equity Incentive Plan.**\n\n** **\n\nThe Company’s stockholders approved the\namendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan, as disclosed in the Company’s definitive proxy statement\nfor the Annual Meeting. The final voting results are as follows:\n\n** **\n\n**Votes For**\n \n**Votes Against**\n \n**Abstentions**\n \n**Broker Non-Votes**\n\n18,094,953\n \n12,793,033\n \n25,879\n \n14,185,811\n\n** **\n\n**Proposal 6. Approval of an Amendment to\nthe Company’s Sixth Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock\nfrom 100,000,000 to 200,000,000.**\n\n** **\n\nThe Company’s stockholders approved the\namendment to the Company’s sixth amended and restated certificate of incorporation to increase the authorized number of the Company’s\ncommon stock, par value $0.001 per share, from 100,000,000 to 200,000,000. The final voting results are as follows:\n\n** **\n\n**Votes For**\n \n**Votes Against**\n \n**Abstentions**\n\n42,417,621\n \n2,655,416\n \n26,639\n\n** **\n\n**Proposal 7. Approval of an Amendment to\nthe Company’s Sixth Amended and Restated Certificate of Incorporation Allowing Officer Exculpation as Permitted by Delaware Law.**\n\n** **\n\nThe Company’s stockholders approved the\namendment to the Company’s sixth amended and restated certificate of incorporation allowing officer exculpation as permitted by\nDelaware law. The final voting results are as follows:\n\n** **\n\n**Votes For**\n \n**Votes Against**\n \n**Abstentions**\n \n**Broker Non-Votes**\n\n29,642,641\n \n1,235,007\n \n36,217\n \n14,185,811\n\n \n\n2\n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**Protara Therapeutics, Inc.**\n\n \n \n \n\nDated: June 15, 2026\nBy:\n/s/ Patrick Fabbio\n\n \n \nPatrick Fabbio\n\n \n \n*Chief Financial Officer*\n\n \n\n3"}